Neoleukin Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>NT</div>
NLTX -- USA Stock  

USD 13.39  0.12  0.90%

It appears Neoleukin Therapeutics will continue to recover much faster as its share price surged up 35.19% today. Neoleukin Therapeutics's current daily volatility is 5.75 percent, with a beta of 0.65 and an alpha of 0.39 over DOW. As many investors are getting excited about pharmaceutical products, it is fair to break down Neoleukin Therapeutics. We will evaluate why recent Neoleukin Therapeutics price moves suggest a bounce in January.
Published over three weeks ago
View all stories for Neoleukin Therapeutics | View All Stories
Breaking down Neoleukin Therapeutics (NASDAQ:NLTX) volatility slide
Neoleukin Therapeutics currently holds roughly 201.15 M in cash with (19.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.8. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neoleukin Therapeutics has an asset utilization ratio of 7582.52 percent. This suggests that the company is making $75.83 for each dollar of assets. An increasing asset utilization means that Neoleukin Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Neoleukin Therapeutics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Neoleukin Therapeutics along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Neoleukin Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Neoleukin Therapeutics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Neoleukin Therapeutics. Your research has to be compared to or analyzed against Neoleukin Therapeutics' peers to derive any actionable benefits. When done correctly, Neoleukin Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Neoleukin Therapeutics.

How important is Neoleukin Therapeutics's Liquidity

Neoleukin Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Neoleukin Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neoleukin Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Neoleukin Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Neoleukin Therapeutics, but it might be worth checking our own buy vs. sell analysis

Neoleukin Therapeutics Correlation with Peers

Investors in Neoleukin can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Neoleukin Therapeutics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Neoleukin Therapeutics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Neoleukin is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Neoleukin for more details

Purchase by Baker Bros Advisors Lp of 518555 shares of Neoleukin Therapeutics

Legal trades by Neoleukin Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neoleukin insider trading alert for perchase of pre-funded warrants by Baker Bros Advisors Lp, the corporate stakeholder, on 23rd of December 2020. This event was filed by Neoleukin Therapeutics In with SEC on 2020-12-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Neoleukin Therapeutics Investor Appetite?

Neoleukin Therapeutics appears to be somewhat reliable, given 1 month investment horizon. Neoleukin Therapeutics has Sharpe Ratio of 0.0932, which conveys that the firm had 0.0932% of return per unit of risk over the last month. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. By analyzing Neoleukin Therapeutics technical indicators you can presently evaluate if the expected return of 0.54% is justified by implied risk. Please exercise Neoleukin Therapeutics Risk Adjusted Performance of 0.1044, mean deviation of 3.53, and Downside Deviation of 4.18 to check out if our risk estimates are consistent with your expectations.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Will Neoleukin Therapeutics current rise continue?

Current coefficient of variation is at 1108.94. Neoleukin Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Neoleukin Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Neoleukin Therapeutics future alpha.

Our Final Take On Neoleukin Therapeutics

While some companies within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Neoleukin Therapeutics may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither trade nor trade any shares of Neoleukin Therapeutics at this time. The Neoleukin Therapeutics risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neoleukin Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Neoleukin Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com